Danaher Financial Model
Laboratory Equipment Company Financials Example (Free Excel Download)
Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services.
professionals from Deloitte
Used by professionals from
About this model
This model provides a comprehensive equity valuation and scenario planning tool for Danaher Corporation (DHR), enabling an analyst to assess the intrinsic value of its post-spin-off, pure-play life sciences and diagnostics portfolio and evaluate the impact of bioprocessing market normalisation.
- Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services.
- Business segments:
- Biotechnology (~30% of revenue)
- Life Sciences (~30% of revenue)
- Diagnostics (~40% of revenue)
- Key geographies: North America (~44-50%), Western Europe (~16-34%), High-Growth Markets (~28-30%), Other Developed Markets (~4-7%).
- Business model type: "Razor/razorblade" model with highly recurring revenue streams (consumables represent 67% to 89% of segment revenues), underpinned by the proprietary Danaher Business System (DBS) which drives continuous operational improvement.
- Competitive position: Market leader in bioprocessing (Cytiva, Pall), clinical diagnostics (Beckman Coulter, Cepheid), and life sciences instruments, competing with Thermo Fisher Scientific, Agilent, and Waters.
- Recent major events: Spun off its Environmental & Applied Solutions segment into an independent publicly traded company, Veralto (VLTO), in September 2023. Acquired Abcam for $5.7 billion in late 2023 to bolster its proteomics portfolio.
The downloadable Danaher financial model includes SEC-sourced historical financials, forecast assumptions, core operating schedules, and valuation outputs in an Excel workbook built for review and scenario analysis.
A turnkey financial model
Live formulas, no hardcoded values
Outputs are driven by live formulas, so the workbook updates from its assumptions instead of relying on hardcoded results.
All assumptions in one tab
Inputs are clearly marked in the Assumptions tab and separated from calculations, making it clear what to change and what to leave intact.
Statements always balancing
For integrated-statement models, the balance sheet, cash flow, and supporting schedules tie through properly.
Distinct schedules for clarity
Debt, working capital, taxes, and cash flow can get messy quickly. We group calculations in clear schedules, not across disconnected tabs.
No hidden macros or external links
There are no unexplained external workbook links or macros to undermine auditability or portability.
Changes flow through the model
Update a key driver and see the impact carry through the forecast, financing, and return outputs. We never use hardcoded numbers in formulas.
Historicals & AssumptionsDanaher financial modelCompany, Historicals & Assumptions used
Source: SEC EDGAR · values in USD
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $24.80B | $26.64B | $23.89B | $23.88B | $24.57B |
| Gross profit | $15.24B | $16.19B | $14.03B | $14.21B | $14.52B |
| Operating income | $6.38B | $7.54B | $5.20B | $4.86B | $4.69B |
| Net income | $6.43B | $7.21B | $4.76B | $3.90B | $3.61B |
Forecast assumptions
Defaults used in the downloadable model. Forecast horizon: FY2026–FY2030.
See 8 moreSee less
How to build a detailed financial model for Danaher
A complete walkthrough of every driver, margin, working-capital input, and capital-allocation assumption used in the downloadable model.
Revenue Deep Dive
Biotechnology
- Segment name: Biotechnology
- Revenue driver formula: Bioprocessing Equipment Volume + (Installed Base x Consumables Usage Rate)
- Historical growth rate: Highly volatile recently (COVID boom followed by destocking); normalised long-term core growth target is high-single digits. Grew 8% in FY2025 to $7.3 billion.
- Key growth levers and headwinds: Driven by FDA approvals of biologic drugs, monoclonal antibody demand, and genomic medicines. Headwinds include inventory destocking by biopharma customers post-COVID.
- Pricing dynamics: High pricing power due to regulatory lock-in (consumables are written into FDA drug manufacturing approvals).
- Revenue recognition notes: Equipment recognised upon delivery/installation; consumables recognised upon shipment. 85% of segment revenue is recurring.
- Seasonality: Generally stable, with a slight uptick in Q4 due to biopharma year-end budget flushes.
Life Sciences
- Segment name: Life Sciences
- Revenue driver formula: Instrument Placements x Average Selling Price + (Installed Base x Consumables/Service Attachment Rate)
- Historical growth rate: Flat in FY2025 ($7.3 billion); historical 3-5% CAGR.
- Key growth levers and headwinds: Driven by global academic and biopharma R&D budgets. Headwinds include constrained capital equipment spending and weakness in the Chinese market.
- Pricing dynamics: Competitive pricing on instruments, high margin on proprietary consumables and service contracts.
- Revenue recognition notes: 67% recurring revenue. Abcam integration adds significant high-margin consumable antibody revenue.
- Seasonality: Q4 is typically the strongest quarter due to academic and corporate capital budget exhaustion.
Diagnostics
- Segment name: Diagnostics
- Revenue driver formula: Core Clinical Testing Volumes + Point-of-Care Respiratory Testing Volumes (Cepheid)
- Historical growth rate: 1.5% growth in FY2025 to $9.9 billion.
- Key growth levers and headwinds: Driven by aging populations, hospital testing volumes, and decentralised point-of-care testing. Headwinds include the normalisation of endemic COVID/flu testing revenues.
- Pricing dynamics: Contractual, volume-based pricing with hospitals and reference labs.
- Revenue recognition notes: 89% recurring revenue (reagents, calibrators, quality controls).
- Seasonality: Stronger in Q1 and Q4 due to the Northern Hemisphere respiratory virus season (flu, RSV, COVID-19).
Cost Structure
Variable Costs / COGS
- Line-by-line breakdown: Direct material costs (chemicals, plastics, electronic components), direct manufacturing labour, overhead, and freight.
- Gross margin range: 58.0% - 61.0% (FY2024 gross margin was 59.5%).
- Key input costs and commodity exposures: Highly engineered plastics, electronic components, and biological raw materials (antibodies, reagents).
- How COGS scales with revenue: High operating leverage. Consumables carry significantly higher gross margins than capital equipment; as the installed base grows, the mix shifts toward consumables, naturally expanding gross margins.
Operating Expenses
- R&D: Typically 6.0% - 7.0% of revenue. Covers new product development, clinical trials for diagnostics, and software engineering. Expensed as incurred.
- SG&A: Typically 28.0% - 30.0% of revenue. Heavily driven by direct sales force headcount, marketing, and corporate administrative functions.
- Depreciation & Amortisation: D&A is substantial due to serial M&A. Amortisation of acquisition-related intangibles (e.g., Cytiva, Abcam) creates a massive wedge between GAAP and Non-GAAP earnings.
- Stock-Based Compensation: Typically 1.0% - 1.5% of revenue.
- Restructuring / one-time charges: Frequent non-cash impairment charges (e.g., $562 million in FY2025 for trade names and technology assets) and integration costs for large acquisitions.
Margin Profile
- Gross margin: 58% - 61%
- EBITDA margin: 31% - 34%
- Operating margin: GAAP operating margin fluctuates (19.1% in FY2025 due to impairments), but Adjusted Operating Margin consistently runs at 28.0% - 29.0%.
- Net margin: 14% - 18% (GAAP).
- Margin trend: Expanding long-term due to the DBS-driven efficiency and a mix shift toward higher-margin consumables and biologics.
Balance Sheet Structure
- Total assets: ~$77 billion to $84 billion.
- Key asset categories: Highly skewed toward Goodwill and Intangible Assets due to historical acquisitions (Cytiva, Pall, Aldevron, Abcam).
- Goodwill & intangibles as % of total assets: Typically 65% - 75% of total assets.
- Working capital profile:
- Days Sales Outstanding (DSO): 45 - 55 days.
- Days Inventory Outstanding (DIO): 80 - 100 days (requires high inventory of biological materials).
- Days Payable Outstanding (DPO): 60 - 75 days.
- Net working capital as % of revenue: Low single digits.
- Is working capital positive or negative? Slightly positive, but DBS implementation ensures working capital grows much slower than revenue, acting as a source of cash during efficiency drives.
- PP&E: Relatively asset-light (~5-7% of total assets). Consists of manufacturing facilities, clean rooms, and leased office space.
- Right-of-use assets / operating leases: Material but manageable, typically $1.0 billion - $1.5 billion.
Capital Expenditure & Investment
- Capex as % of revenue: 5.0% - 6.0% (FY2024 capex was ~$1.39 billion).
- Maintenance capex vs. growth capex: Approximately 40% maintenance, 60% growth (expanding bioprocessing manufacturing capacity).
- Major capex programmes underway or planned: Expansion of Cytiva manufacturing footprint and Abcam integration facilities.
- Capitalised software / development costs: Minimal relative to total capex.
- M&A pattern: Serial acquirer. Historically transformational (Pall, Cytiva), recently focused on large bolt-ons (Aldevron, Abcam).
- Typical acquisition multiple paid: High multiples (often 15x-25x EBITDA) justified by target market growth and DBS synergy extraction.
Debt & Capital Structure
- Total debt: ~$16.0 billion (as of FY2024/2025).
- Debt/EBITDA ratio: Current ~1.8x - 2.2x. Target is typically below 3.0x to maintain investment-grade ratings.
- Credit rating: A- (S&P) / Baa1 (Moody's).
- Key debt instruments: Senior unsecured notes (USD and EUR denominated) and commercial paper.
- Maturity profile: Well-laddered with average maturity exceeding 5 years.
- Interest rate profile: Predominantly fixed-rate bonds.
- Covenants: Standard investment-grade covenants; no restrictive financial maintenance covenants that are currently at risk.
- Share repurchase programme: Highly active. Deployed ~$7 billion toward repurchases in 2024/early 2025.
- Dividend policy: Low yield but consistent growth. $0.40 per quarter ($1.60 annualised), representing a payout ratio of ~20% of net income.
Cash Flow Characteristics
- Operating cash flow conversion: OCF / Net Income typically >120% due to heavy non-cash amortisation.
- Free cash flow margin: FCF / Revenue typically 21% - 23% (FY2025 FCF was $5.3 billion on $24.6 billion revenue).
- Major non-cash items that bridge net income to OCF: Amortisation of acquisition-related intangibles, depreciation, stock-based compensation, and impairment charges.
- Working capital cash flow impact: DBS drives continuous working capital improvements, often making it a net source of cash.
- Capex intensity: Moderate (5-6% of revenue).
- Cash tax rate vs. GAAP effective tax rate: Cash taxes are typically lower than the GAAP effective tax rate (~18-20%) due to the tax deductibility of certain goodwill/intangible amortisation and R&D credits.
Sheet Structure
- Assumptions: Hardcoded drivers for revenue growth by segment, margin profiles, working capital days, capex, and tax rates.
- Scenarios: Base, Bull, and Bear cases toggling bioprocessing recovery speed and Cepheid respiratory testing volumes.
- Income Statement: Consolidated GAAP income statement mirroring the 10-K, with a clear bridge to Non-GAAP Adjusted Net Earnings (adding back amortisation and impairments).
- Balance Sheet: Standard format, breaking out Goodwill, Intangible Assets, and Right-of-Use Assets clearly.
- Cash Flow Statement: Indirect method starting from Net Earnings from Continuing Operations.
- Revenue & Segment Build: Detailed build for Biotechnology, Life Sciences, and Diagnostics, splitting out recurring vs. non-recurring revenue.
- Working Capital Schedule: DSO, DIO, DPO calculations feeding the CFS.
- Depreciation & Amortisation: Waterfall schedule separating PP&E depreciation from acquisition-related intangible amortisation.
- Debt Schedule: Tranche-by-tranche debt build, interest expense calculation, and commercial paper tracking.
- Shareholders Equity & Shares: Tracking retained earnings, dividends, and the impact of the massive share repurchase programme.
- DCF Valuation: Unlevered free cash flow build, WACC calculation, and terminal value using the perpetuity growth method.
Key Financial Relationships
- `Biotechnology Revenue = Prior Year Biotechnology Revenue x (1 + Biotech Core Growth Rate + M&A Impact)`
- `Life Sciences Revenue = Prior Year Life Sciences Revenue x (1 + Life Sciences Core Growth Rate)`
- `Diagnostics Revenue = Prior Year Diagnostics Revenue x (1 + Diagnostics Core Growth Rate)`
- `Total Revenue = Biotechnology Revenue + Life Sciences Revenue + Diagnostics Revenue`
- `Gross Profit = Total Revenue x Gross Margin %`
- `SG&A Expense = Total Revenue x SG&A % of Revenue`
- `R&D Expense = Total Revenue x R&D % of Revenue`
- `Adjusted Operating Profit = Gross Profit - SG&A Expense - R&D Expense` (Excludes amortisation of acquisition-related intangibles and impairments)
- `GAAP Operating Profit = Adjusted Operating Profit - Amortisation of Intangibles - Impairment Charges`
- `Accounts Receivable = (Total Revenue / 365) x DSO`
- `Inventory = (COGS / 365) x DIO`
- `Accounts Payable = (COGS / 365) x DPO`
- `Free Cash Flow = Operating Cash Flow - Capital Expenditures + Capital Disposals`
- `Diluted Shares Outstanding = Prior Year Shares - (Share Repurchase Spend / Average Share Price)`
Cross-Sheet Dependencies
- The Revenue & Segment Build is the critical engine, feeding the top line of the Income Statement.
- Income Statement Net Earnings feeds the top of the Cash Flow Statement and Retained Earnings on the Balance Sheet.
- Working Capital Schedule calculates changes in AR, Inventory, and AP, which feed the operating section of the Cash Flow Statement.
- Depreciation & Amortisation feeds operating expenses on the Income Statement and is added back on the Cash Flow Statement.
- Debt Schedule calculates Interest Expense for the Income Statement and ending debt balances for the Balance Sheet. Circularity risk exists here if interest expense is tied to average debt balances funded by a revolving credit facility; use a circularity breaker toggle.
Sign Convention
- Income Statement: Revenues are positive. All expenses (COGS, SG&A, R&D, Interest, Taxes) are negative.
- Balance Sheet: Assets are positive. Liabilities and Equity are positive.
- Cash Flow Statement: Net Income is positive. Non-cash add-backs (D&A) are positive. Increases in assets (use of cash) are negative. Increases in liabilities (source of cash) are positive. Capex is negative. Dividends and share repurchases are negative. Debt issuance is positive; debt repayment is negative.
Things Most Likely to Go Wrong
- Veralto Spin-Off Distortion: Historical financials prior to Q4 2023 include the Environmental & Applied Solutions segment. The model must strictly use "Continuing Operations" data to ensure comparability.
- GAAP vs. Non-GAAP EPS: Danaher's GAAP EPS is heavily depressed by the amortisation of acquisition-related intangibles. Valuing the company on GAAP P/E will result in severe mispricing; the model must calculate Adjusted Diluted Net Earnings per Share.
- Impairment Noise: The company frequently takes large non-cash impairment charges (e.g., $562M in 2025). These must be excluded from core operating margin calculations.
- Respiratory Testing Volatility: Cepheid's respiratory testing revenue creates massive seasonal and year-over-year swings in the Diagnostics segment.
- Bioprocessing Destocking: The Biotechnology segment experienced negative growth in 2023/2024 due to customer destocking. Extrapolating historical averages will fail; the model must assume a return to normalised high-single-digit growth by 2026.
- Share Count Reduction: Failing to model the aggressive share repurchase programme ($7B recently deployed) will understate future EPS.
- Currency Translation: With over 50% of revenue outside North America, FX swings can impact reported revenue by 2-3%. The model should forecast on a constant-currency core growth basis.
Validation Checks
- "FCF to Net Income conversion must be >100% (Danaher has achieved this for 33 consecutive years)."
- "Gross margin should remain in the 58.0% - 61.0% band; flag if it drops below 58%."
- "Adjusted Operating Margin should be in the 28.0% - 30.0% range."
- "Capex as a % of revenue should be between 5.0% and 6.0%."
- "Total Assets must exactly equal Total Liabilities + Shareholders' Equity in all forecast periods."
- "Debt/EBITDA should not exceed 3.0x without triggering a warning regarding the credit rating."
- "Dividend payout ratio should remain around 20% of net income based on historical policy."
Key Assumptions (Default Values)
| Assumption | Default Value | Unit | Rationale |
|---|---|---|---|
| Biotechnology Core Growth | 6.0 | % | Return to normalised high-single-digit growth post-destocking |
| Life Sciences Core Growth | 3.0 | % | Modest improvement in end markets and academic funding |
| Diagnostics Core Growth | 4.0 | % | Steady clinical volumes offsetting respiratory normalisation |
| Gross Margin | 59.5 | % | Based on FY2024 actuals and stable pricing power |
| SG&A % of Revenue | 29.0 | % | Historical average, maintaining DBS efficiencies |
| R&D % of Revenue | 6.5 | % | Consistent with historical investment levels |
| Days Sales Outstanding (DSO) | 50 | Days | Historical average for continuing operations |
| Days Inventory Outstanding (DIO) | 90 | Days | Historical average, reflecting biological materials supply chain |
| Days Payable Outstanding (DPO) | 65 | Days | Historical average |
| Capex % of Revenue | 5.5 | % | Based on FY2024 actuals ($1.39B on $23.9B revenue) |
| Effective Tax Rate | 19.0 | % | Management guidance and historical average |
| Share Repurchase Annual Spend | 2,500 | $ Millions | Normalised run-rate post the massive 2024/2025 deployment |
| Dividend per Share | 1.60 | $ | Current annualised dividend ($0.40/quarter) |
| WACC | 7.5 | % | Standard for large-cap, diversified life sciences tools |
| Terminal Growth Rate | 3.0 | % | Aligns with long-term global healthcare spending growth |
Data Sources & Benchmarks
- Filings: SEC EDGAR (Form 10-K, 10-Q, 8-K), Danaher Investor Relations website (Earnings Presentations, 2025 Sustainability Report).
- Key Peers for Benchmarking: Thermo Fisher Scientific (TMO), Agilent Technologies (A), Waters Corporation (WAT), Illumina (ILMN).
- Industry Data Sources: IQVIA (for clinical trial and biopharma pipeline data), EvaluatePharma (for biologic drug approval trends).
- Consensus Estimates: Bloomberg or FactSet for consensus core growth and adjusted EPS estimates.
Sources
- Danaher Corporation FY2024 Form 10-K (SEC EDGAR)
- Danaher Corporation Q4 and Full Year 2025 Earnings Release (January 28, 2026)
- Danaher Investor Relations Presentations (www.danaher.com/investors)
- Press releases regarding the Veralto spin-off (September 2023) and Abcam acquisition (August/December 2023)
Do more with the Danaher model
Frequently asked
What does Danaher Corporation (DHR) do and what are its main business segments?+
Danaher is a global science and technology innovator that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. Its primary business segments include Biotechnology, Life Sciences, and Diagnostics, with Diagnostics contributing approximately 40% of its revenue. The company operates a "razor/razorblade" model, generating highly recurring revenue from consumables.
How does Danaher generate revenue, and what is its core business model?+
Danaher primarily generates revenue through a "razor/razorblade" business model, where the sale of instruments drives recurring sales of high-margin consumables. Consumables represent a significant portion of segment revenues, ranging from 67% to 89%. This model is underpinned by the proprietary Danaher Business System (DBS), which focuses on continuous operational improvement.
What are the key financial assumptions for Danaher's revenue growth and operating expenses in its financial model?+
The financial model for Danaher assumes a revenue growth rate of approximately 7.47%. Key operating expense assumptions include COGS at about 41.47% of revenue, R&D at 6.08% of revenue, and SGA at 29.41% of revenue. These percentages are crucial for projecting the company's future profitability and cash flows.
What is Danaher's capital expenditure strategy and working capital profile?+
Danaher's capital expenditure is projected at approximately 4.42% of revenue, with about 60% allocated to growth capex, specifically for expanding bioprocessing manufacturing capacity. The company maintains a slightly positive net working capital profile, typically low single digits as a percentage of revenue. The Danaher Business System ensures working capital grows much slower than revenue, often acting as a source of cash.
What is the primary purpose of the Danaher (DHR) financial model and what can it help assess?+
The Danaher financial model serves as a comprehensive equity valuation and scenario planning tool. It enables analysts to assess the intrinsic value of Danaher's post-spin-off life sciences and diagnostics portfolio. Additionally, the model helps evaluate the impact of bioprocessing market normalization on the company's financial performance.
Is an Excel financial model available for Danaher (DHR) and what is its forecast period?+
Yes, an Excel financial model for Danaher (DHR) is available for download. This model provides a detailed forecast horizon covering fiscal years 2026 through 2030. It allows for in-depth analysis of the company's future financial performance and valuation.
Have more financial modelling questions? Contact us
Created by ex-finance professionals
Hey, I’m Alex and I created Finamodel.
Over my years in the finance industry I kept building the same models over and over again. Same structure, same assumptions, different logo. So I started building frameworks to turn them into clean, reusable templates.
Every model here is one I’d actually use for a client, and I personally vet each one before it goes up.
I’m not an expert in every industry, but I’ve built enough models to know what belongs in one. And when something is completely foreign to me, I reach out to my network for experts to work on our models with us.
Having a template library on hand cuts a first build from hours to minutes.
Need help finding your model? You’ll find me in the Finamodel app!
Other Laboratory Equipment Company Financial Models
Browse another company in the same sector.
Agilent Technologies
Agilent Technologies is a global leader in life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow.
Mettler Toledo
Mettler Toledo is a global manufacturer of precision instruments and services for use in laboratory, industrial, and food retailing applications.
Revvity
Revvity provides health science solutions, technologies, and services spanning discovery, development, and diagnosis, offering instruments, reagents, and informatics software through its Life Sciences and Diagnostics segments, including newborn screening platforms.
Bio-Techne
Bio-Techne Corporation (TECH) is a global life sciences company that develops, manufactures, and sells bioactive reagents, analytical instruments, and precision diagnostics for the research and clinical diagnostic markets.
Thermo Fisher Scientific
Thermo Fisher Scientific is the world's largest supplier of scientific instrumentation, reagents, consumables, and software to life sciences, clinical, and industrial laboratories.
Waters
Waters Corporation designs, manufactures, sells, and services analytical instruments, primarily liquid chromatography and mass spectrometry systems.
Explore more Healthcare financial model templates.
